Search

The biotech company, a world leader in the industrial production of Tenebrio molitor, breaks ground on its new 90,000 m2 plant, which will have an annual production capacity of more than 100,000 tons

Biotechnology has radically changed the treatment of many types of tumors, evolving from highly aggressive and non-specific treatments to those tailored to the unique characteristics of each patient.

As part of the BCN Health Innovation Week, IOMED is hosting the event “European Health Data Space – How to Leverage Data from Clinical Practice.” This session will take place on February 19 at the

HispanIA 2040 is a strategic study promoted by the Spanish National Office of Foresight and Strategy, compiled by 12 experts from the public sector, academia and industry, including Dr Marc Güell, CSO

Both entities are jointly participating in the OVERCAD project, which aims to develop a new effective therapeutic strategy for the treatment of resistant ovarian cancer, focusing on an Antibody-Drug

Aimed at enhancing U.S. outreach, investor relations, corporate dialogue, and business development (BD) capabilities.

Meet GEA, our new member. We spoke with Miguel Molina, Sales Manager Chemical & Pharma.

GENESIS Biomed directly invested €50,000 in Corify Care in this round as a sign of commitment to the project. This is the 21st round of funding that the consultancy has helped to close since its

Study led by Medical College of Wisconsin and exploring the combination with azacitidine.

Dr. Beaurang has over 25 years of experience in biotechnology focusing on corporate strategy, business development, oncology, immunology and neurology.

This report aims to provide an overview of the most promising emerging developments to serve as a reference for Europe's priorities and align with the EU's innovation policy.

Interview Francisco Fernández-Avilés – Professor of Cardiovascular Medicine at the UCM and Co-Founder of Corify Care.

We interviewed Lidya Domínguez, Director of Clinical Research at Sermes CRO, experts in European clinical trial regulation and CTIS, who have been involved in its development since 2017 as members of

Out of the 930 studies authorized by the AEMPS last year, a total of 52 focused on advanced therapy medicines.